Biggest News Aggregation in the World
📰 Nasdaq Elev News

Nasdaq Elev News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Elev. Real-time updates on events, politics, business and more.

Short Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Drops By 10.8%

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 593,500 shares, a decrease of 10.8% from the November 15th total of 665,100 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average trading volume […]
Virtu Financial Renaissance Technologies Millennium Management Elevation Oncology Inc Blackrock Inc Annandale Capital

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Down 10.8% in November

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 593,500 shares, a decline of 10.8% from the November 15th total of 665,100 shares. Based on an average daily trading volume, of 218,500 […]
Elevation Oncology Inc Sphera Funds Management Bio Partners Walleye Capital Elevation Oncology Get Free Report

Caxton Corp Sells 46,599 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV)

Caxton Corp decreased its holdings in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) by 68.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,725 shares of the company’s stock after selling 46,599 shares during the period. Elevation Oncology makes up approximately 0.1% of […]
Caxton Corp Blackrock Inc Annandale Capital Millennium Management Virtu Financial Elevation Oncology Inc

Elevation Oncology (NASDAQ:ELEV) Stock Rating Reaffirmed by Wedbush

Wedbush reiterated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. Wedbush also issued estimates for Elevation Oncology’s Q4 2023 earnings at ($0.26) EPS, FY2023 earnings at ($1.21) EPS, Q1 2024 […]
Annandale Capital Elevation Oncology Company Profile Virtu Financial Millennium Management Elevation Oncology Inc Jpmorgan Chase Co

Elevation Oncology (NASDAQ:ELEV) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $1.50 target price on the stock. Elevation Oncology Stock Up 1.9 % ELEV opened at $0.68 on Friday. The firm has […]
Millennium Management Elevation Oncology Inc Blackrock Inc Renaissance Technologies Jpmorgan Chase Co Annandale Capital
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Comparing Elevation Oncology (NASDAQ:ELEV) & Monte Rosa Therapeutics (NASDAQ:GLUE)

Elevation Oncology (NASDAQ:ELEV – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation. Volatility & Risk Elevation Oncology has […]
New York United States Monte Rosa Therapeutics Inc Elevation Oncology Inc Megalith Biopharmaceutical Co Ltd Oncology Inc

Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Significant Drop in Short Interest

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the target of a significant drop in short interest in July. As of July 15th, there was short interest totalling 1,320,000 shares, a drop of 11.4% from the June 30th total of 1,490,000 shares. Based on an average daily volume of 1,940,000 shares, the short-interest ratio […]
Blackrock Inc Millennium Management Elevation Oncology Inc Jpmorgan Chase Co Virtu Financial Renaissance Technologies
Source: wkrb13.com

BML Capital Management LLC Makes New Investment in Elevation Oncology, Inc. (NASDAQ:ELEV)

BML Capital Management LLC bought a new position in shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 39,963 shares of the company’s stock, valued at approximately $38,000. Elevation Oncology accounts for 0.0% […]
United States Millennium Management Elevation Oncology Inc Bml Capital Management Annandale Capital Virtu Financial

Elevation Oncology (NASDAQ:ELEV) Upgraded at SVB Securities

SVB Securities upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a report issued on Tuesday, The Fly reports. SVB Securities currently has $8.00 target price on the stock, up from their previous target price of $5.00. Separately, Wedbush reiterated an outperform rating and set […]
United States Elevation Oncology Company Profile Elevation Oncology Inc Tang Capital Management Sio Capital Management Renaissance Technologies

Elevation Oncology (NASDAQ:ELEV) Upgraded at SVB Leerink

SVB Leerink upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a research report report published on Tuesday morning, PriceTargets.com reports. A number of other analysts have also recently issued reports on ELEV. Wedbush restated an outperform rating and set a $4.00 price objective on […]
United States Tang Capital Management Elevation Oncology Inc Sio Capital Management Geode Capital Management Renaissance Technologies

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science